Drug Trial Radar · NCT02550080
Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome
Last checked: Nov 19, 2026Latest source record: Mar 3, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,130
Planned (sponsor's estimate)
Start
Jul 2015
Primary completion
Dec 2018
Study completion May 2019
Sponsor
- Lead sponsor
- Shandong Provincial Institute of Dermatology and VenereologyAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Shandong Provincial Hospital; Jinan Central Hospital; Shandong Qianfo Hospital; Jinan Military General Hospital; Qingdao Hiser Medical Group; Liaocheng People's Hospital; Dongying People's Hospital; Jining First People's Hospital; Dezhou People's Hospital; Jinan City Dermatology Hospital Prevention and Treatment; Linyi City Dermatology Hospital Prevention and Treatment; Jining City Dermatology Hospital Prevention and Treatment; Weifang City Dermatology Hospital Prevention and Treatment; Laiwu City Dermatology Hospital Prevention and Treatment; Rizhao City Dermatology Hospital Prevention and Treatment
- First posted
- Sep 15, 2015
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Study is to evaluate the utility of prospective HLA-B\*1301 screening on the incidence of dapsone hypersensitivity syndrome (DHS) in 3130 previously Dapsone(DDS)-naive patients. Those patients include allergic cutaneous vasculitis, urticaria, psoriasis, acne, bullous skin diseases, sterile pustulosis, leprosy, pneumocystis pneumonia and any other patients who need dapsone administration. The study has two (co-primary) objectives: i) to determine if screening for HLA-B\*1301 prior to DDS-containing treatment results in a lower incidence of clinically-suspected DHS versus current standard of care (no genetic screening) and ii) to determine if screening for HLA-B\*1301 prior to DDS-containing treatment results in a significantly lower incidence of immunologically-confirmed DHS versus current standard of care (no genetic screening or patch testing). The study consists of up to a 5-day screening period, a randomised observation period (Day 1 through Week 6) and, for subjects experiencing a suspected DHS and a subset of DDS-tolerant subjects, an epicutaneous patch test (EPT) assessment period. Eligible subjects will be randomised to one of two study arms: a Current Standard of Care Arm (no prospective genetic screening: Control) and a Genetic Screening Arm (prospective genetic screening: Case). Subjects identified as HLA-B\*1301 positive in the prospective Genetic Screening Arm will not receive dapsone and will be excluded from further study. Subjects who experience suspected DHS during the 6-week observation would be withdrawn from dapsone and undergo EPT patch testing 6 weeks later.
Conditions
- Allergic Cutaneous Vasculitis
- Urticaria
- Psoriasis
- Acne
- Bullous Skin Diseases
- Sterile Pustulosis
- Leprosy
- Pneumocystis Pneumonia
Interventions
DapsoneDrug
For the HLA-B\*1301 positive subjects, dapsone will not be administrated.
HLA-B*1301Genetic
The prospective genetic screening group will be tested before administrating dapsone
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of clinically-suspected DHS during the 6-week observation periodTime frame: 6 weeks
- Incidence of immunologically-confirmed DHS during the 6-week observation periodTime frame: 6 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shandong Provincial Institute of Dermatology and Venereology
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.